ASAQ Winthrop®

Sanofi

Legend
Product category

  • Artemisinin-based Combination Therapy (ACT)

  • Artesunate-amodiaquine
Therapeutic indication
  • Treatment of uncomplicated P. falciparum malaria in adults, children and infants >5kg
Dosing

  • Once-daily for 3 days
Efficacy

  • 28 day PCR-corrected ACPR* 94.4%–98.9%
Key features

  • Low price compared to other prequalified ACTs (public-sector tenders)

  • Three-year shelf life
Challenges

  • Amodiaquine resistance in some countries

  • Being withdrawn from countries where SPAQ is deployed for seasonal malaria chemoprevention (SMC) following WHO recommendation
Status

  • 537 million treatments distributed since 2007

  • Approved in 33 countries (see map)
Previously

  • DNDi and partners completed development and registration. Incorporated into MMV portfolio via collaboration supporting phase IV safety study in Côte d’Ivoire in 2010
MMV Project Director
  • Adam Aspinall

* ACPR = adequate clinical and parasitological response